For MS, Early Intensive Therapy Beats Escalation Approach, Study Shows Everyday Health MenuNewslettersSearch Multiple Sclerosis
Early Aggressive MS Treatment Superior to Escalation Approach Study Shows
New research confirms that starting MS therapy with more effective drugs slows disability progression in people with RRMS. By Brian P. DunleavyReviewed: September 9, 2021Fact-CheckedFinding the right MS medication can make a big difference in future function.Getty Images Starting on a highly effective disease-modifying therapy (DMT) — as opposed to switching from less-effective to more-effective treatments or gradually increasing medication doses based on symptoms — slows disability progression in people with relapsing-remitting multiple sclerosis (RRMS), a study published on August 16 in JAMA Neurology found. The so-called “Swedish treatment strategy” encourages the use of stronger, more effective DMTs in people with RRMS earlier in the course of the disease. The idea is that earlier initiation with these more effective drugs slows the rate of disability worsening, as measured on a standardized scale. RELATED: MS Medications Balancing Drug Efficacy With Safety and Side Effects
In the past, some neurologists have held off on using these more effective drugs in some people with MS due to their side effects. Instead, they’ve opted to initiate treatment with less effective, but safer, drugs at lower doses and increase the doses or switch to stronger therapies, as needed, based on disease activity, or relapses. “Our study supports the growing body of evidence that early treatment with highly efficacious drugs is advantageous, at least over the older treatment escalation [approach],” says study coauthor Tim Spelman, MD, PhD, a professor of clinical neuroscience at Karolinska Institute in Stockholm. Study Compares Swedish With Danish MS Treatment Strategy
The study compared the effectiveness of MS treatment in Sweden, where neurologists have the “flexibility” to start people with RRMS on highly effective DMTs, to that in Denmark, where the treatment escalation strategy remains standard, Dr. Spelman says. To do so, Spelman and his colleagues collected medical data on 2,700 people with RRMS in Sweden and 2,161 in Denmark. They compared “disability worsening” after six months of MS treatment in study participants, based on Expanded Disability Status Scale (EDSS) scores. The EDSS is a widely used tool for quantifying physical disability caused by MS. Individuals who had started a DMT between 2013 and 2016 were included in the analysis, and their progress over time was noted. Among the Swedish participants, roughly 35 percent started treatment with a highly effective DMT compared with just under 8 percent of those in Denmark. Taking a Highly Effective DMT Reduces Rate of Disability Worsening
The Swedish participants who were started on a highly effective DMT saw a 29 percent larger reduction in the rate of disability worsening after six months of treatment than the Danish participants who were managed using the treatment escalation approach, Spelman and his colleagues report. In addition, the participants started on a highly effective DMT experienced a 24 percent reduction in the rate of reaching an EDSS score of 3, compared with the Danish participants. Those started on a highly effective DMT took more than two years to reach an EDSS score of 3, while those on treatment escalation took a little more than 18 months. Furthermore, Swedish participants started on highly effective DMT took nearly four years to reach an EDSS score of 4, while the Danish participants did so more than a year earlier. Meanwhile, Swedish participants were 22 percent less likely to discontinue treatment and 12 percent less likely to switch treatments, due to lack of results, than their Danish counterparts, the researchers say. Differing National Strategies
In Sweden in recent years, the monoclonal antibody Rituxan (rituximab), which is considered a high-efficacy treatment, is increasingly being used as a first-line treatment for RRMS. This is in spite of Rituxan not being approved treat MS in Sweden. As it is in the United States and elsewhere in the world, Rituxan must be administered off-label in Sweden. Conversely, in Denmark, 42 percent of the study participants were started on Aubagio (teriflunomide), which was the most frequent first-line treatment, followed by interferon beta-1a, in 30 percent, according to Spelman and his colleagues. Both Aubagio and interferon beta-1a are considered to have the lowest efficacy of the MS therapies, according to UpToDate. How the Results Can Be Applied Elsewhere in the World
“Even though other healthcare settings and countries are certainly more diverse in terms of patient population [than Sweden and Denmark], we would argue that by selecting two very similar and homogenous national settings, we were able to more directly attribute differences in clinical outcome to the national treatment strategy itself,” Spelman notes. “This in turn provides additional real-world evidence supporting early initiation of highly efficacious therapy across other settings outside of Scandinavia,” he concludes. NEWSLETTERS Sign up for our Multiple Sclerosis Newsletter
SubscribeBy subscribing you agree to the Terms of Use and Privacy Policy. The Latest in Multiple Sclerosis
How to Craft a Life s Mission Statement
By Trevis GleasonOctober 21, 2022 Dysarthria When MS Makes It Hard to Speak
By Mona SenOctober 20, 2022 Is That Really How I Walk
By Trevis GleasonOctober 18, 2022 How Do You Know When to Throw in the Towel
By Trevis GleasonOctober 14, 2022 Living With MS What to Know About Neuropathic Pain and How to Manage It
Neuropathic pain is not your average pain. Here’s what to know about this unique type of MS pain and how to find relief.By Kerry WeissOctober 12, 2022 UTIs and MS The Importance of Early Diagnosis and Treatment
If you have multiple sclerosis, you may be prone to frequent urinary tract infections. Besides being painful, UTIs can make MS worse, so it’s important...By Kerry WeissOctober 12, 2022 Why Is Orange the Color of MS
By Trevis GleasonOctober 11, 2022 13 Celebrities Who Have Multiple Sclerosis
Look among the millions of people with multiple sclerosis and you'll find famous faces, too. Learn how some of these celebrities are dealing with MS and...By Regina Boyle WheelerOctober 11, 2022 We All Have Something to Teach Our MS Doctors
By Trevis GleasonOctober 7, 2022 EBV An MS Box I Can Finally Tick
By Trevis GleasonOctober 4, 2022 MORE IN MS and Your Menstrual Cycle Does One Affect the Other
UTIs and MS The Importance of Early Diagnosis and Treatment
What Top MS Researchers Want You to Know About MS Care and Treatment Right Now